China's Sinopharm says data 'better than expected' from it's COVID vaccine trial
1 min read . Updated: 11 Nov 2020, 06:46 PM IST
Premium- Sinopharm's unit CNBG has moved two vaccine candidates into Phase 3 clinical trials outside China in multiple countries including the UAE, Bahrain and Egypt
- It did not offer details on the better-than-expected data, or specify which vaccine candidate the data are generated from
China National Pharmaceutical Group (Sinopharm) said on Wednesday the data from large-scale, late-stage clinical trials for its unit's COVID-19 vaccine are "better than expected".
Sinopharm's unit China National Biotec Group (CNBG) has moved two vaccine candidates into Phase 3 clinical trials outside China in multiple countries including the United Arab Emirates, Bahrain and Egypt involving more 50,000 participants in total.
The trials are nearing their ends, Sinopharm said in a statement on Chinese social media WeChat.
It did not offer details on the better-than-expected data, or specify which vaccine candidate the data are generated from.
This story has been published from a wire agency feed without modifications to the text.
